IDH1 and central nervous system cancer: report that five patients with grade II glioma harboring BRAFV600E without IDH1 mutation who had undergone gross total resection without treatment were progression-free for 14–35 months; two patients with glioblastoma harboring BRAFV600E and IDH1WT had a progression-free survival of 36 and 19 months, respectively (36).